Large Language Models in Drug Discovery: Practices and Trends Across the Full R&D Pipeline

Introduction: LLMs Evolving from Support Tools to R&D Core

In recent years, the penetration of large language models (LLMs) into vertical industries has outpaced expectations. In pharmaceuticals, long-standing pain points—development cycles of 10–15 years and average costs exceeding billions of dollars—create natural ground for AI adoption. Multiple technology companies and cutting-edge biotech teams have begun embedding LLMs deeply into drug discovery, preclinical research, and regulatory workflows. Early public results already show quantifiable efficiency gains.

This article uses publicly disclosed industry cases to systematically outline the technical logic, typical scenarios, and future trends of LLM applications at each stage of AI-driven drug development, helping developers, R&D managers, and technical decision-makers build a comprehensive picture of “AI + pharma.”

Technical Applications of LLMs Across Drug R&D Stages

2.1 Molecular Design and Candidate Screening

Molecular design is where drug discovery begins. Traditional approaches rely on high-throughput screening (HTS) and experience-driven lead compound optimization—processes that are time-consuming and yield limited hit rates. By learning from massive datasets linking molecular structures to biological activity, LLMs contribute in several ways:

• Generative molecular design: Given a target protein structure and known active scaffolds, models can generate novel molecular structures with desired physicochemical properties (e.g., solubility, metabolic stability, blood-brain barrier permeability).
• Multi-objective optimization: Simultaneously balancing target binding affinity, selectivity, synthetic accessibility, and toxicity predictions to produce a Pareto-optimal candidate set.
• Rapid iteration: With AI-assisted coding tools, researchers can automate the generation and preliminary evaluation of thousands to tens of thousands of candidates within weeks—a process that traditionally takes months when done manually.

One frontier team’s practice illustrates this: using LLM-assisted coding tools, the team autonomously generated roughly 35,000 antibody design proposals in about one month, then screened for effective candidates against a specific immune target. Several candidates showed binding and dissociation profiles superior to existing standard drugs. This exemplifies a “LLM generation + expert validation” human-AI collaboration paradigm.

2.2 Manufacturing Document Review and Quality Compliance

Drug manufacturing involves vast volumes of process documents, batch records, and change-control filings. LLMs add value here by:

• Automated document comparison: Performing semantic-level diff detection between current and historical manufacturing documents against regulatory requirements, rapidly flagging non-compliant items.
• Pre-submission compliance checks: Drawing on structured understanding of global pharmaceutical regulations to pre-review submission documents and reduce the risk of rejection.
• Knowledge-augmented retrieval: Using a RAG (Retrieval-Augmented Generation) architecture so the model cites the latest regulatory text when answering compliance questions, ensuring traceability.

Industry data indicates that LLM-assisted review can multiply document audit efficiency several-fold while significantly reducing human error rates.

2.3 Regulatory Filing and Clinical Trial Planning

Regulatory submissions (e.g., IND, NDA) are critical gates for advancing drugs into clinical use. LLMs support this through:

• Structured generation of submission materials: Auto-populating technical document sections based on target-market regulatory templates, reducing repetitive work.
• Intelligent clinical protocol assistance: Leveraging disease epidemiology data, prior trial results, and statistical models to help design trial endpoints, inclusion/exclusion criteria, and sample-size estimates.
• Multilingual translation and localization: Providing high-quality multi-language document conversion for global submissions.

One team has publicly stated plans to extend LLM involvement into human clinical trials—meaning models will move beyond the “document layer” into core trial-design decision-making.

Case Studies: From Concept to Mouse Studies in 18 Months

3.1 The “One-Person Biotech” Model

A highly representative case involves a solo researcher operating a micro biotech team. Using LLMs to coordinate contracts, logistics, and experimental schedules across 11 external labs—and delegating much of the operational workload to AI—the researcher advanced a candidate therapy for a rare pediatric muscle-wasting disease from concept to mouse studies in under 18 months, with preliminary positive results.

Key takeaways:

1. AI as a “virtual CTO/COO”: The LLM participated not only in scientific decisions but also in project management, vendor coordination, and contract drafting—non-research but mission-critical operations.
2. Leverage for small teams: AI gave a single person or tiny team the development throughput that traditionally required dozens of people, dramatically lowering the organizational barrier for rare-disease drug development.
3. Compressed validation loop: The cycle from target hypothesis to animal-model validation was sharply shortened, laying groundwork for future human trials.

According to disclosures, if the candidate continues to perform well, it could be ready to enter human clinical trials as early as late 2028—a timeline that aligns with the industry’s widely anticipated window for the first AI-designed drugs to reach human testing.

3.2 Genetic Instruction Optimization for Cell Therapies

Another notable direction is the engineering of cell therapies such as CAR-T. While CAR-T has achieved strong results in hematologic cancers, expanding into solid tumors faces challenges of target specificity and durability.

A research team demonstrated that six scientists, using AI-assisted coding tools, designed novel genetic instruction fragments for a key component of their therapy. One design was approximately 70% shorter than the standard version; lab tests showed the engineered immune cells produced roughly 10× the receptor count of the original, achieved higher tumor-cell killing efficiency, and remained active longer.

Technical implications:

• Shorter genetic constructs reduce vector packaging difficulty and improve transduction efficiency.
• Higher receptor expression directly boosts the effector cells’ targeted killing capacity.
• Longer persistence may address the core problem of T-cell exhaustion in the solid-tumor microenvironment.

Ecosystem Collaboration: Multi-Institutional Coverage of the Full Pipeline

Beyond individual teams, the industry has developed a multi-institutional collaborative ecosystem. Over recent months, several leading research organizations have partnered with LLM technology providers to cover stages from early discovery through clinical planning. Typical collaboration patterns include:

Collaboration Stage	Typical Application	Core Value
Early Discovery	Target validation, lead compound generation	Shorten discovery timelines
Molecular Optimization	Antibody design, genetic instruction engineering	Improve candidate quality
Preclinical Research	Animal model design, toxicology prediction	Reduce failure risk
Clinical Planning	Trial protocol design, endpoint selection	Increase approval likelihood

This full-pipeline coverage signals that LLMs are no longer a single-stage “efficiency booster” but are becoming an “infrastructure layer” spanning the drug development lifecycle.

Technical Architecture and Implementation Guidance

5.1 Recommended Technology Stack

Teams looking to introduce LLM capabilities into pharma R&D should consider the following architecture:

• Foundation model layer: Select general-purpose LLMs with strong reasoning and long-context capabilities, combined with domain fine-tuning (e.g., SFT on molecular descriptors or biological sequence data).
• Knowledge augmentation layer: Build a RAG pipeline connected to structured and unstructured sources such as patent databases, clinical trial registries, and regulatory document repositories.
• Tool-calling layer: Use Function Calling mechanisms to interface with molecular simulation software, Laboratory Information Management Systems (LIMS), and document management platforms.
• Safety and compliance layer: Deploy data de-identification, audit logging, and access controls to meet GxP compliance requirements in the pharmaceutical industry.

5.2 Key Implementation Principles

1. Human-AI collaboration, not replacement: LLM outputs must be reviewed by domain experts, especially for safety and efficacy judgments.
2. Data quality first: Pharma data is highly sensitive and uneven in quality; data governance is a prerequisite for project success.
3. Iterative validation loop: Every AI-generated candidate must enter wet-lab verification, forming a “generate → screen → test → feedback → regenerate” cycle.
4. Compliance up front: For stages involving human trials, engage regulators early on the boundaries and transparency requirements for AI-assisted decision-making.

Outlook and Challenges

LLM-powered AI pharma is at a pivotal inflection point, moving from proof-of-concept to scalable deployment. Around 2028, the first candidates deeply designed with AI entering human clinical trials will mark a major milestone.

Challenges, however, are real: model hallucination tolerance is extremely low in high-stakes medical contexts; the complexity of biological systems far exceeds current model understanding; and data silos and privacy barriers persist. Only by advancing technology, regulation, and ethics in parallel can AI’s transformative potential in pharma be fully unlocked.

For developers, this is a golden opportunity to intersect cutting-edge AI capabilities with life sciences. Understanding drug R&D business logic, mastering domain-adapted model fine-tuning, and building compliant, auditable technical systems will be the core competencies for riding this wave.